Résumé
La grippe reste une cause de morbidité et de mortalité importante dans notre pays. La vaccination annuelle des populations à risque, reste la meilleure arme préventive, afin de limiter les coûts de la santé. La couverture vaccinale des personnes âgées et des professionnels de la santé en Suisse est pour l'instant insuffisante. Il apparait nécessaire de développer des programmes d'information, de sensibilisation et de motivation dans la communauté, sur le plan national, certainement avec l'appui des caisses-maladies. Le remboursement du vaccin depuis 1996, pour les personnes à risque, suite à la modification de la loi sur l'assurance maladie va certainement contribuer à promouvoir la vaccination antigrippale. D'autre part, la concurrence des différents vaccins mis sur le marché pharmaceutique suisse, ces dernières années, va favoriser la diffusion de l'information et faire progresser la couverture vaccinale.
Summary
Influenza is still an important cause of morbidity and mortality in our country. The yearly vaccination of the population at risk is always the best method of prevention and for the limitation of health care costs. Today the protection of elderly people and health care professionals by vaccination is not sufficient. Development of information programs, sensibilisation and motivation of the community on a national basis and in line with the health care insurers are necessary. The vaccin's reimboursment since 1996 following the respective legal change will certainly help to promote vaccination against influenza. On the other hand, the competition of different vaccins introduced in Switzerland in the last years will additionally support the penetration of information and vaccination.
Zusammenfassung
Die Grippe hat als Morbiditäts- und Mortalitätsursache nach wie vor einen bedeutenden Stellenwert in unserem Land. Am besten wird sie präventiv durch die alljährliche Impfung von Risikogruppen bekämpft, was nicht zuletzt auch die Gesundheitskosten in Schranken hält. Die Durchimpfung der Betagten sowie der Belegschaften im Gesundheitswesen der Schweiz ist derzeit ungenügend. Die Entwicklung eines Informationsprogramms, die Sensibilisierung und Motivation der Bevölkerung auf nationaler Ebene im Einklang mit den Versicherungen sind vonnöten. Die seit 1996 im Rahmen des neuen Krankenversicherungsgesetzes eingeführte Kostenübernahme durch die Krankenkassen für Risikopatienten ist ein weiterer Meilenstein zur Ausbreitung der Grippeimpfung. Auch die kompetetive Vielfalt der Impfstoffe, die in den letzten Jahren im Schweizer-Pharmamarkt eingeführt wurden, trägt zur Informationsausbreitung und zur erweiterten Durchimpfung bei.
This is a preview of subscription content, log in via an institution to check access.
Références
Bundesamt für Gesundheit. Empfehlungen zur Grippeprävention. BAG-Bulletin 1996; 38 suppl XIII: 1–20.
Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–1978. Am J Public Health 1986;76: 761–765.
Lui KJ, Kendal AP Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77: 712–716.
Egger M, Jennings S, Spuhler Th, Zimmermann HP, Paccaud F, Somaini B Sterblichkeit während Grippepidemien in der Schweiz 1969–1985. Schweiz Med Wochenschr 1989;119: 434–439.
Monto AS, Ohmit SE, Margulies JR, Talsma AN. Medical practice-base influenza surveillance: Viral prevalence and assesment of morbidity. Am J Epidemiol 1995;142: 4–5.
Peritta DM, Deckmann M, Glizen WP. Acute respiratory disease hospitalizations as a mesure of impact of epidemic influenza. Am J Epidemiol 1985;142: 468–475.
Mc Bean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993;153: 2105–2111.
Chappuis S, Paccaud MF, Wunderli W. Surveillance of influenza in Switzerland between 1987 and 1995; 142:4–5. Schweiz Med Wochenschr 1996;126: 1135–1142.
Patriarca PA, Weber JA, Parker RA et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A(H3N2) epidemic. JAMA 1985;253: 1136–1139.
Meiklejohn G, Hoffmann R, Graves P. Effectiveness of influenza vaccine when given during an outbreak of influenza A/H3N2 in a nursing home. J Am Geriatr Soc 1989;37: 407–410.
Foster DA, Talsma A, Furumoto et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136: 296–307.
Fedson DS, Wajda A, Nicod P, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Mannitoa. JAMA 1993;270: 1956–1961.
Gross PA, Hermogenes AW, Sacks HS, Lau J, Lewandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123: 518–527.
Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost effectiveness in a health maintenance organization. Ann Intern Med 1994;121: 947–952.
Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly living in the community. N Engl J Med 1994;331: 778–784.
Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333: 889–893.
Fedson DS, Hannoun C, Leese J et al. Influenza vaccination in 18 developed countries, 1980–1992. Vaccine 1995;13: 623–627.
GEIG. Groupe d'étude et d'information sur la grippe. Dossier de presse. Campagne d'information 1994 sur la vaccination contre la grippe. Bilan de 3 campagnes contre la grippe 1991–1993, 1–7.
Pneumococcal andinfluenza vaccination levels among adults aged >65 years-United States 1993. MMWR 1996;45:853–859.
Healthy People: National Health Promotion and Disease Prevention Objectives. Washington DC US sept of Health and Human Services, Public Health Service; 1990.
Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives-full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service; 1991: 122–3; DHHS publication no (PHS)91-50213.
Centers for Disease Control. Prevention and control of influenza. Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45 (RR-5): 1–26.
Gauthey L, Toscani L, Chamot E et al. Influenza vaccination coverage in the geriatric population of the state of Geneva, Switzerland. Accepted for publication in the European Journal of Public Health.
Barazzoni F. Vaccination contre la grippe des personnes âgées hébergées dans les institutions tessinoises: une analyse de la couverture vaccinale et du rapport coût-efficacité de la vaccination. Cahiers médico-sociaux 1993;37: 287–296.
Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–1990 epidemic. Lancet 1995;346: 591–595.
Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of health care workers in long term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175: 1–6.
Mazrou AAI, Scheifele DW, Soong T et al. Comparison of adverse reactions to whole-virion and splitvirion influenza vaccines in hospital personnel. Can Med Assoc J 1991;145: 622–626.
Gauthey L, Martin R, Herrmann F, Karsegard J, Michel JP. Effets secondaires de la vaccination antigrippale chez les personnes âgées deplus de 60 ans. Ann Med Interne 1996;147: 10–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gauthey, L., Toscani, L. & Schira, JC. Vaccination contre la grippe en Suisse. Soz Präventivmed 42, S107–S111 (1997). https://doi.org/10.1007/BF01365164
Issue Date:
DOI: https://doi.org/10.1007/BF01365164